Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-19T14:32:37.879Z Has data issue: false hasContentIssue false

Chapter 12 - A neurobehavioralist approach to the management of cognitive impairment in Parkinson's disease

from Section II - Management of Nonmotor Symptoms of Parkinson's Disease

Published online by Cambridge University Press:  05 March 2016

By
Po-Heng Tsai
Edited by
Néstor Gálvez-Jiménez ,
Hubert H. Fernandez ,
Alberto J. Espay  and
Susan H. Fox
Néstor Gálvez-Jiménez
Affiliation:
Cleveland Clinic, Florida
Hubert H. Fernandez
Affiliation:
Cleveland Clinic, Ohio
Alberto J. Espay
Affiliation:
University of Cincinnati
Susan H. Fox
Affiliation:
Toronto Western Hospital
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Parkinson's Disease
Current and Future Therapeutics and Clinical Trials
 , pp. 122 - 126
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Jankovic, J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2007; 79: 368–76.CrossRefGoogle Scholar
Lim, SY, Fox, SH, Lang, AE. Overview of the extranigral aspects of Parkinson disease. Arch Neurol 2009; 66: 167–72.CrossRefGoogle ScholarPubMed
Barone, P, Antonini, A, Colosimo, C, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009; 24: 1641–9.CrossRefGoogle ScholarPubMed
Emre, M, Aarsland, D, Brown, R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689–707.CrossRefGoogle ScholarPubMed
Aarsland, D, Bronnick, K, Williams-Gray, C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010; 75: 1062–9.CrossRefGoogle ScholarPubMed
Litvan, I, Aarsland, D, Adler, CH, et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011; 26: 1814–24.CrossRefGoogle ScholarPubMed
Watson, GS, Leverenz, JB. Profile of cognitive impairment in Parkinson's disease. Brain Pathol 2010; 20: 640–5.Google Scholar
Petersen, RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183–194.CrossRefGoogle ScholarPubMed
Aarsland, D, Brønnick, K, Larsen, JP, Tysnes, OB, Alves, G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009; 72: 1121–6.CrossRefGoogle ScholarPubMed
Litvan, I, Goldman, JG, Tröster, AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27: 349–56.CrossRefGoogle ScholarPubMed
Chou, KL, Amick, MM, Brandt, J, et al. A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Mov Disord 2010; 25: 2501–7.CrossRefGoogle ScholarPubMed
Dalrymple-Alford, JC, MacAskill, MR, Nakas, CT, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010; 75: 1717–25.CrossRefGoogle ScholarPubMed
Emre, M, Aarsland, D, Albanese, A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509–18.CrossRefGoogle ScholarPubMed
Klein, JC, Eggers, C, Kalbe, E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010; 74: 885–92.CrossRefGoogle ScholarPubMed
Rolinski, M, Fox, C, Maidment, I, McShane, R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012; 3: CD006504.Google Scholar
Lipton, SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J Alzheimers Dis 2004; 6 (Suppl.): S61–74.CrossRefGoogle ScholarPubMed
Svenningsson, P, Westman, E, Ballard, C, Aarsland, D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol 2012; 11: 697–707.CrossRefGoogle ScholarPubMed
Marsh, L, Biglan, K, Gerstenhaber, M, Williams, JR. Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord 2009; 24: 277–82.CrossRefGoogle ScholarPubMed
Weintraub, D, Mavandadi, S, Mamikonyan, E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010; 75: 448–55.CrossRefGoogle ScholarPubMed
Hanagasi, HA, Gurvit, H, Unsalan, P, et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 2011; 26: 1851–8.CrossRefGoogle ScholarPubMed
Parsons, TD, Rogers, SA, Braaten, AJ, Woods, SP, Tröster, AI. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol 2006; 5: 578–88.CrossRefGoogle ScholarPubMed
Smeding, HM, Speelman, JD, Huizenga, HM, Schuurman, PR, Schmand, B. Predictors of cognitive and psychosocial outcome after STN-DBS in Parkinson's Disease. J Neurol Neurosurg Psychiatry 2011; 82: 754–60.CrossRefGoogle ScholarPubMed
Buschert, V, Bokde, AL, Hampel, H. Cognitive intervention in Alzheimer disease. Nat Rev Neurol 2010; 6: 508–17.Google Scholar
Hindle, JV, Petrelli, A, Clare, L, Kalbe, E. Nonpharmacological enhancement of cognitive function in Parkinson's disease: a systematic review. Mov Disord 2013; 28: 1034–49.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×